|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:atccode
|
J02 AC01
|
|
gptkbp:available_on
|
gptkb:cream
gptkb:tablet
gptkb:hair_care_product
|
|
gptkbp:brand
|
gptkb:Nizoral
|
|
gptkbp:casnumber
|
65277-42-1
|
|
gptkbp:chemical_formula
|
C26 H28 Cl2 N4 O4 S
|
|
gptkbp:contraindication
|
liver disease
pregnancy
breastfeeding
|
|
gptkbp:developed_by
|
gptkb:Janssen_Pharmaceutica
|
|
gptkbp:discovered_by
|
1970s
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ketoconazole
|
|
gptkbp:interacts_with
|
gptkb:cyclosporine
gptkb:warfarin
benzodiazepines
|
|
gptkbp:is_analyzed_in
|
hormonal therapies
antifungal resistance
|
|
gptkbp:is_associated_with
|
drug interactions
QT prolongation
|
|
gptkbp:is_available_in
|
gptkb:various_countries
|
|
gptkbp:is_considered
|
first-line treatment for certain fungal infections
second-line treatment for others
|
|
gptkbp:is_not_recommended_with
|
gptkb:beer
gptkb:fruit
|
|
gptkbp:is_part_of
|
combination therapy
treatment protocols
antifungal therapy
clinical guidelines for antifungal treatment
|
|
gptkbp:is_studied_for
|
new formulations
alternative delivery methods
|
|
gptkbp:is_subject_to
|
prescription regulations
|
|
gptkbp:is_used_in
|
treatment of prostate cancer
treatment of Cushing's syndrome
|
|
gptkbp:mechanism_of_action
|
inhibits ergosterol synthesis
|
|
gptkbp:metabolism
|
liver enzymes
|
|
gptkbp:route_of_administration
|
oral
topical
|
|
gptkbp:side_effect
|
dizziness
headache
nausea
liver toxicity
|
|
gptkbp:suitable_for
|
gptkb:children
elderly patients
patients with adrenal insufficiency
|
|
gptkbp:used_for
|
fungal infections
seborrheic dermatitis
candidiasis
tinea infections
|
|
gptkbp:bfsParent
|
gptkb:Head_&_Shoulders,_Inc.
gptkb:Ranitidine
|
|
gptkbp:bfsLayer
|
6
|